GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Second Sight Medical Products Inc (NAS:EYESW) » Definitions » Valuation Rank

EYESW (Second Sight Medical Products) Valuation Rank


View and export this data going back to 2017. Start your Free Trial

What is Second Sight Medical Products Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Second Sight Medical Products Valuation Rank Related Terms

Thank you for viewing the detailed overview of Second Sight Medical Products's Valuation Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Second Sight Medical Products Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Second Sight Medical Products Inc (NAS:EYESW) » Definitions » Valuation Rank
Comparable Companies
SONX LUCD LHDX LNSR AZYO VAPO CFMS ISO CTSO MOVE ABT MDT SYK EW BSX SZSE:300760 DXCM ZBH STE ALGN
Traded in Other Exchanges
N/A
Address
13170 Telfair Avenue, Sylmar, CA, USA, 91342
Website
https://www.secondsight.com
Second Sight Medical Products Inc develops, manufactures, and markets implantable prosthetic devices to create an artificial form of useful vision for blind individuals. The company's product Argus II System treats outer retinal degenerations, such as Retinitis Pigmentosa, often referred to as RP. The company generates revenue from the sale of its Argus II retinal prosthesis systems, which include the implant and external components. Geographically, the company operates in the United States, Italy, China, and of which key revenue is derived from the United States.